BriaCell closes spinout of BriaPro, distributes shares to existing shareholders

BriaCell Therapeutics Corp.

BriaCell completed spinout of BriaPro, receiving 2/3 ownership; shareholders get one BriaPro share and one new BriaCell share per old share.
BriaPro acquired pipeline assets Bria-TILsRx™ and PKCδ inhibitors for cancer indications.
New BriaCell common shares expected to begin trading on or about September 5, 2023 under symbol BCT.
BriaCell remains listed on Nasdaq and TSX; BriaPro is an unlisted reporting issuer in Canada.
Computershare will distribute certificates; letters of transmittal mailed to registered holders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.